➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
McKesson
AstraZeneca
Express Scripts
Johnson and Johnson

Last Updated: September 17, 2021

DrugPatentWatch Database Preview

Investigational Drug Information for AZD6738


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug AZD6738?

AZD6738 is an investigational drug.

There have been 28 clinical trials for AZD6738. The most recent clinical trial was a Phase 1 trial, which was initiated on September 1st 2019.

The most common disease conditions in clinical trials are Carcinoma, Lung Neoplasms, and Neoplasms. The leading clinical trial sponsors are AstraZeneca, Samsung Medical Center, and National Cancer Institute (NCI).

There are five US patents protecting this investigational drug and forty-two international patents.

Recent Clinical Trials for AZD6738
TitleSponsorPhase
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or GeneNational Cancer Institute (NCI)Phase 1
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung CancerAstraZenecaPhase 2
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung CancerMuhammad FurqanPhase 2

See all AZD6738 clinical trials

Clinical Trial Summary for AZD6738

Top disease conditions for AZD6738
Top clinical trial sponsors for AZD6738

See all AZD6738 clinical trials

US Patents for AZD6738

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AZD6738 ⤷  Try it Free Chemical compounds Astrazeneca AB (Sodertalje, SE) ⤷  Try it Free
AZD6738 ⤷  Try it Free Chemical compounds AstraZeneca AB (Sodertalje, SE) ⤷  Try it Free
AZD6738 ⤷  Try it Free Chemical compounds AstraZeneca AB (Sodertalje, SE) ⤷  Try it Free
AZD6738 ⤷  Try it Free Chemical compounds AstraZeneca AB (Sodertalje, SE) ⤷  Try it Free
AZD6738 ⤷  Try it Free Chemical compounds AstraZeneca AB (Sodertalje, SE) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AZD6738

Drugname Country Document Number Estimated Expiration Related US Patent
AZD6738 Argentina AR081859 2030-06-11 ⤷  Try it Free
AZD6738 Australia AU2011263491 2030-06-11 ⤷  Try it Free
AZD6738 Brazil BR112012031561 2030-06-11 ⤷  Try it Free
AZD6738 Canada CA2800203 2030-06-11 ⤷  Try it Free
AZD6738 Chile CL2012003503 2030-06-11 ⤷  Try it Free
AZD6738 China CN103068391 2030-06-11 ⤷  Try it Free
AZD6738 Colombia CO6640270 2030-06-11 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Merck
Express Scripts
Baxter
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.